The observation that pharmacologic inhibition of Angptl4 in the liver recapitulates the amelioration of metabolic parameters observed following its genetic ablation (i.e., protection against diet-induced obesity, dyslipidemia, glucose intolerance, and liver damage) highlighted the potential of this factor as a therapeutic target for metabolic diseases. This evidence concerns the gene ANGPTL4 and metabolic syndrome.